Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 55.59 -0.95 (-1.68%) Market Cap: 3.47 Bil Enterprise Value: 3.14 Bil PE Ratio: 0 PB Ratio: 308.96 GF Score: 58/100

Rhythm Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 01:00PM GMT
Release Date Price: $25.22 (+2.11%)
Joohwan Kim
Canaccord Genuity Group - Analyst

Hi, everyone. Thanks for attending Cannacord Genuity's 43rd Annual Growth Conference. My name is Joohwan Kim, and I'm an associate of (inaudible) and Rare Diseases. We're very excited to have the team from Rhythm Pharmaceuticals here. And it's my great pleasure to introduce David Meeker who is the Chair, CEO, and President. Rhythm is a global biopharmaceutical company leading the space for hyperphagia, a severe obesity caused by rare MC4R pathway diseases.

And so with that, I'll turn it over to the presentation.

David Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President, and CEO

So thank you, Joohwan, and welcome, everybody. Apologies for my voice. As you can tell, I'm recovering here in terms of some form of laryngitis. And I think I'm well on the way, but apologies if it's a little harder to understand.

So Rhythm, this is our forward-looking statement. Obviously, I'm not going to read through it. For the slides, this is our corporate deck. It's available on our website, and I won't be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot